

## The Lebanese LSIDCM

# Search for hits and early leads from soil bacteria to combat infectious diseases

Jennifer Herrmann

*Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research, Saarland University, Saarbrücken, Germany*

### Abstract

**Introduction:** Natural products are the source of a large fraction of the current pharmaceuticals available against human disease. However, the discovery of novel compounds with new mechanisms of action is becoming increasingly challenging. We focused our work on soil-dwelling Myxobacteria from highly diverse samples, which are more and more recognized as an important natural product source.

**Methodology:** Our discovery pipeline combines traditional whole cell-based activity screens with state-of-the-art analytical techniques and a comprehensive dereplication process. Having identified an antimicrobial compound we aim at elucidating its target, MOA and MOR in diverse microbiological screens and by applying 'omic' technologies.

**Results:** Two case studies of currently investigated compound classes will be highlighted. Cystobactamids are novel topoisomerase inhibitors that display very pronounced activity on Gram-positive and Gram-negative bacteria. Telomycins from *Streptomyces canus* bind to cardiolipin and our studies revealed other putative cellular targets.

**Conclusion:** We were able to isolate several new natural products with potent and selective activity against clinically relevant pathogens. Interestingly, underlying MOAs often differ from those of already described antimicrobial agents.

**Key words:** myxobacteria; streptomyces; natural products.

*J Infect Dev Ctries* 2018; 12(2S):24S. doi:10.3855/jidc.10096

(Received 21 December 2017 – Accepted 23 December 2017)

Copyright © 2018 Herrmann. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Corresponding author

Jennifer Herrmann  
Helmholtz Institute for Pharmaceutical Research Saarland  
Department Microbial Natural Products  
Helmholtz Centre for Infection Research  
Saarland University Campus E8.1  
66123 Saarbrücken, Germany  
Email: jennifer.herrmann@helmholtz-hzi.de

**Conflict of interests:** No conflict of interests is declared.